Alnylam Pharmaceuticals Inc
ALNY392.240USD
+52.440+15.43%
Handelsschluss 07/31, 16:00（ET）Kurse um 15 Minuten verzögert
51.11BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Alnylam Pharmaceuticals Inc Unternehmen
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Unternehmensinformationen
BörsenkürzelALNY
Name des UnternehmensAlnylam Pharmaceuticals Inc
IPO-datumMay 28, 2004
Gegründet am2003
CEODr. Yvonne L. Greenstreet, M.D.
Anzahl der mitarbeiter2230
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse675 W Kendall St
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142-1168
Telefon16175518200
Websitehttps://www.alnylam.com/
BörsenkürzelALNY
IPO-datumMay 28, 2004
Gegründet am2003
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.35K
--
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
+3.87%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
+21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.35K
--
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
+3.87%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
+21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
AMVUTTRA
309.99M
52.17%
GIVLAARI
66.97M
11.27%
Other
57.56M
9.69%
Regeneron Pharmaceuticals
51.04M
8.59%
ONPATTRO
49.49M
8.33%
Other
59.15M
9.95%
Nach RegionUSD
Name
Umsatz
Anteil
United States
271.44M
45.68%
Europe
146.16M
24.60%
Net revenues from collaborations
99.19M
16.69%
Rest of World
50.94M
8.57%
Royalty revenue
26.47M
4.45%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
AMVUTTRA
309.99M
52.17%
GIVLAARI
66.97M
11.27%
Other
57.56M
9.69%
Regeneron Pharmaceuticals
51.04M
8.59%
ONPATTRO
49.49M
8.33%
Other
59.15M
9.95%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital World Investors
12.85%
Fidelity Management & Research Company LLC
11.22%
The Vanguard Group, Inc.
9.97%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
55.32%
Aktionäre
Aktionäre
Anteil
Capital World Investors
12.85%
Fidelity Management & Research Company LLC
11.22%
The Vanguard Group, Inc.
9.97%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
55.32%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
67.07%
Investment Advisor/Hedge Fund
20.96%
Corporation
3.41%
Hedge Fund
3.14%
Sovereign Wealth Fund
1.98%
Research Firm
1.57%
Pension Fund
1.29%
Bank and Trust
1.12%
Individual Investor
0.40%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1290
132.21M
101.40%
-2.93M
2025Q1
1315
132.55M
101.67%
-2.42M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
16.75M
12.85%
+149.10K
+0.90%
Mar 31, 2025
Fidelity Management & Research Company LLC
14.62M
11.22%
+1.68M
+13.00%
Mar 31, 2025
The Vanguard Group, Inc.
13.00M
9.97%
+322.72K
+2.55%
Mar 31, 2025
Capital Research Global Investors
7.15M
5.49%
+186.22K
+2.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.73M
5.16%
-22.21K
-0.33%
Mar 31, 2025
Regeneron Pharmaceuticals Inc
4.44M
3.41%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
4.42M
3.39%
+33.70K
+0.77%
Mar 31, 2025
Baillie Gifford & Co.
3.66M
2.81%
-382.65K
-9.47%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.41M
2.61%
+178.26K
+5.52%
Mar 31, 2025
State Street Global Advisors (US)
3.37M
2.58%
-56.29K
-1.64%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Tema Neuroscience and Mental Health ETF
5.92%
VanEck Biotech ETF
5.43%
Global X Genomics & Biotechnology ETF
5.37%
Invesco Nasdaq Biotechnology ETF
4.43%
ProShares Ultra Nasdaq Biotechnology
4.22%
First Trust NYSE Arca Biotechnology Index Fund
4.02%
iShares Biotechnology ETF
3.98%
American Century Focused Dynamic Growth ETF
3.44%
Franklin Genomic Advancements ETF
3.41%
SPDR S&P Biotech ETF
2.75%
Mehr Anzeigen
Tema Neuroscience and Mental Health ETF
Anteil5.92%
VanEck Biotech ETF
Anteil5.43%
Global X Genomics & Biotechnology ETF
Anteil5.37%
Invesco Nasdaq Biotechnology ETF
Anteil4.43%
ProShares Ultra Nasdaq Biotechnology
Anteil4.22%
First Trust NYSE Arca Biotechnology Index Fund
Anteil4.02%
iShares Biotechnology ETF
Anteil3.98%
American Century Focused Dynamic Growth ETF
Anteil3.44%
Franklin Genomic Advancements ETF
Anteil3.41%
SPDR S&P Biotech ETF
Anteil2.75%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
